Abstract
BackgroundPatients with ruptured gastrointestinal stromal tumor (GIST) are recommended for imatinib adjuvant therapy; however, their clinicopathological features and prognosis in the era of imatinib are unknown.Patients and MethodsThe study cohort included 665 patients with histologically proven primary GISTs who underwent R0 or R1 surgery between 2003 and 2007; the validation cohort included 182 patients between 2000 and 2014. The definitions of tumor rupture in the study included perforation at tumor site, tumor fracture, piecemeal resection including open biopsy, and macroscopic injuries to the pseudocapsule.ResultsTumor rupture occurred in 21 (3.2%) of 665 and 5 (2.9%) of 182 patients in the study and validation cohort, respectively. Ruptured GISTs were more symptomatic, were larger in size, and had higher mitotic count than nonruptured GISTs but were not associated with tumor location or laparoscopic surgery. GISTs with intraoperative rupture had clinicopathological features and prognostic outcomes similar to those with preoperative rupture. Recurrence rates were higher and median recurrence-free survival (RFS) and overall survival (OS) were shorter with ruptured than nonruptured GIST. Tumor rupture was one of the independent prognostic factors for RFS, but not OS, according to multivariate analysis.ConclusionsRuptured GISTs were symptomatic larger tumors with high mitotic activity, frequent relapse, and shorter RFS. Tumor rupture was an independent prognostic factor for RFS, but not for OS, in the era of imatinib.
Highlights
Patients with ruptured gastrointestinal stromal tumor (GIST) are recommended for imatinib adjuvant therapy; their clinicopathological features and prognosis in the era of imatinib are unknown
665 patients with primary GIST who underwent R0 or R1 surgery were included in the study cohort and 172 patients in the validation cohort
This study found that ruptured GIST was seen in nearly 3% of primary GISTs, being more symptomatic and exhibiting aggressive features of larger size and higher mitotic count compared with nonruptured tumors
Summary
Patients with ruptured gastrointestinal stromal tumor (GIST) are recommended for imatinib adjuvant therapy; their clinicopathological features and prognosis in the era of imatinib are unknown. The study cohort included 665 patients with histologically proven primary GISTs who underwent R0 or R1 surgery between 2003 and 2007; the validation cohort included 182 patients between 2000 and 2014. Tumor rupture occurred in 21 (3.2%) of 665 and 5 (2.9%) of 182 patients in the study and validation cohort, respectively. Ruptured GISTs were more symptomatic, were larger in size, and had higher mitotic count than nonruptured GISTs but were not associated with tumor location or laparoscopic surgery. GISTs with intraoperative rupture had clinicopathological features and prognostic outcomes similar to those with preoperative rupture
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have